Pentazocine and naloxone hydrochlorides tablets USP contain pentazocine hydrochloride USP, equivalent to 50 mg base, a member of the benzazocine series (also known as the benzomorphan series), and naloxone hydrochloride USP, equivalent to 0.5 mg base. Pentazocine and naloxone hydrochlorides tablets are an analgesic for oral administration.
|Pentazocine and naloxone hydrochlorides tablets are intended for oral use only. Severe, potentially lethal, reactions may result from misuse of pentazocine and naloxone hydrochlorides tablets by injection either alone or in combination with other substances. (See DRUG ABUSE AND DEPENDENCE section.)|
Pentazocine and naloxone hydrochlorides tablets are indicated for the relief of moderate to severe pain.
Pentazocine and naloxone hydrochlorides tablets are indicated for oral use only.
Media Articles Related to Pentazocine and Naloxone (Pentazocine / Naloxone)
Temple study suggests a novel approach for treating non-cardiac chest pain
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2014.10.24]
Chest pain doesn't necessarily come from the heart. An estimated 200,000 Americans each year experience non-cardiac chest pain, which in addition to pain can involve painful swallowing, discomfort...
Extra-Depth Shoes May Help Ease Foot Pain in Elderly
Source: Medscape NeurologyHeadlines [2014.10.23]
For seniors with disabling foot pain, off-the-shelf extra-depth footwear reduced pain and improved function in a new study.
Reuters Health Information
Changing how primary-care doctors treat pain, fatigue and other common symptoms
Source: Pain / Anesthetics News From Medical News Today [2014.10.23]
Common symptoms such as pain or fatigue account for over half of all doctor's office appointments in the United States, translating into more than 400 million visits annually.
Health Tip: Coping With Chronic Pain
Source: MedicineNet Chronic Pain Specialty [2014.10.23]
Title: Health Tip: Coping With Chronic Pain
Category: Health News
Created: 10/23/2014 12:00:00 AM
Last Editorial Review: 10/23/2014 12:00:00 AM
Tear duct implant effective at reducing pain and inflammation in cataract surgery patients
Source: Eye Health / Blindness News From Medical News Today [2014.10.21]
The first tear duct implant developed to treat inflammation and pain following cataract surgery has been shown to be a reliable alternative to medicated eye drops, which are the current standard of...
Published Studies Related to Pentazocine and Naloxone (Pentazocine / Naloxone)
Effect of acute topical application of +-pentazocine on the mechanical allodynia in diabetic mice. [2010.09.01]
Mechanical allodynia is a major complication in diabetic mellitus. Peripheral sigma(1) receptors were shown to be involved in nociceptive perception... This attenuation may be, in part, due to the normalization of increased peripheral NO contents in the hindpaw of diabetic mice.
Hazards of pentazocine for neonatal analgesia: a single-centre experience over 10 years. [2008.09]
BACKGROUND: In developing countries, neonatal analgesia for surgical procedures is a major challenge where postoperative care is inadequate. AIM: To report experience of pentazocine for neonatal surgery in a Nigerian tertiary hospital... CONCLUSION: The use of pentazocine in neonates was associated with high morbidity and mortality. Caution is required when using pentazocine for neonatal analgesia where post-operative respiratory support is insufficient.
Improvement of memory impairment by (+)- and (-)-pentazocine via sigma, but not kappa opioid receptors. [2005.09.28]
(+/-)-Pentazocine is widely used clinically to treat mild to moderate pain as a racemic compound. Although it is known that (-)-pentazocine acts as a kappa opioid receptor agonist to exhibit analgesic actions and (+)-pentazocine acts as a sigma receptor agonist without analgesic effects, their combined effect on memory has not been investigated in detail.
Clinical Trials Related to Pentazocine and Naloxone (Pentazocine / Naloxone)
Effects of Pentazocine Versus Lorazepam or Placebo on Manic Symptoms [Recruiting]
Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals.
To follow up these initial findings, we plan to conduct a larger, more rigorous,
double-blind study. We will examine whether pentazocine, an agent with kappa-opiate
activity, decreases manic symptoms.
Effects of Pentazocine on Manic Symptoms [Active, not recruiting]
The opiate neurotransmitter system is thought to be involved in many abnormal mood states.
Some researchers have suggested that changes in this system may trigger the switch to/from
manic and depressive states in bipolar disorder. One problem with most of the currently
available opiate medications is that they can produce addiction/dependence. A particular
kind of opiate medication known as kappa-opiates may be able to produce changes in this
system with much less risk of addiction. This study looks at Talwin (a combination of
pentazocine and naloxone), a medication which affects the kappa and mu opiate systems. The
study will examine whether two doses of Talwin affect manic symptoms in people who have been
admitted to the hospital. This study will give more information about the involvement of the
opiate system in bipolar disorder, and give important information for use in developing new